“Limit risks for the patient”
Luca Augsburger and his partner, Rafik Ouared, started StrokeLab in September 2008 to facilitate the treatment of brain aneurysms.
Often discovered by chance in visits to the doctor, asymptomatic aneurysms affect 2-4% of the Swiss population. Even so, more than nine cases out of ten are treated unnecessarily because the aneurysm would not have had any consequences for the patient. “Treatment involves assumption of superfluous risk for the patient and considerable cost to the health system,” notes Luc Augsburger.
Rewarded for the two first venture kick stages with 30,000 Swiss francs in financing, StrokeLab provides complementary information to doctors confronted with aneurysm cases. Based on a numerical simulation of blood flow and associated with a morphological analysis of the patient and his/her pathology, this technique contributes to the medical diagnosis, without taking its place. “It’s always a delicate operation, particularly in cases where metal filaments are inserted in the weakened areas of an artery.”
The calculations of blood flow volumes, and pressure and friction analyses associated with each aneurysm profile also allow StrokeLab to evaluate the effectiveness of various different treatment methods in a personalized way.